Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Harmony Biosciences Holdings, Inc. Market Cap
The Harmony Biosciences Holdings, Inc. (HRMY) share price is expected to increase by 35.88% over the next year. This is based on calculating the average 12-month share price estimate provided by 9 stock analysts who have covered HRMY. Price targets range from $28 at the low end to $59 at the high end. The current analyst consensus for HRMY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assignedHRMY 7 buy ratings, 0 hold ratings, and 2 sell ratings. This means that analysts expect Harmony Biosciences Holdings, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HRMY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HRMY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Charles Duncan Cantor Fitzgerald | Overweight | $58 | Maintains | Oct 30, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Oct 30, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $59 | Reiterates | Oct 30, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Oct 29, 2024 |
| Graig Suvannavejh Mizuho | Outperform | $52 | Maintains | Oct 10, 2024 |
| Danielle Brill Raymond James | Outperform | $40 | Reinstates | Oct 10, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Oct 2, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Sep 24, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Sep 12, 2024 |
| Ashwani Verma UBS | Buy | $56 | Initiates | Sep 10, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Aug 6, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Jun 25, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Jun 24, 2024 |
| David Hoang Citigroup | Buy | $48 | Initiates | Jun 21, 2024 |
| Ami Fadia Needham | Buy | $52 | Maintains | May 1, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 30, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $49 | Reiterates | Apr 12, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 11, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 9, 2024 |
When did it IPO
2020
Staff Count
246
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jeffrey M. Dayno M.D.
Market Cap
$1.89B
In 2023, HRMY generated $582.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HRMY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Harmony Biosciences (NASDAQ: HRMY) for potential federal securities law violations related to concerns raised about its drug Wakix in a Scorpion Capital report.
Why It Matters - The investigation into Harmony Biosciences for potential securities law violations and concerns over its drug Wakix could impact stock performance and investor confidence.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Harmony Biosciences Holdings (NASDAQ: HRMY) for potential federal securities law violations linked to concerns raised by Scorpion Capital regarding its drug Wakix.
Why It Matters - The investigation into Harmony Biosciences for potential securities law violations raises concerns about the company's regulatory compliance and market perception, impacting investor confidence and stock performance.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Harmony Biosciences Holdings (NASDAQ: HRMY) for potential federal securities law violations linked to concerns over its narcolepsy drug, Wakix.
Why It Matters - The investigation into Harmony Biosciences could indicate potential legal or financial issues, affecting stock performance and investor confidence in the company.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Harmony Biosciences (NASDAQ:HRMY) for possible federal securities law violations, following concerns raised about its narcolepsy drug, Wakix, in a March 2023 report.
Why It Matters - The investigation into Harmony Biosciences could indicate potential legal and financial risks, impacting stock performance and investor confidence in the company.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will participate in Citi's 2024 Global Healthcare Conference on December 3 and the Piper Sandler Healthcare Conference on December 4, 2024.
Why It Matters - Harmony Biosciences' participation in major investor conferences signals potential growth opportunities and increased visibility, which can impact investor sentiment and stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky has launched an investigation into Harmony Biosciences (NASDAQ: HRMY) for potential federal securities law violations related to concerns over its drug, Wakix, raised by Scorpion Capital.
Why It Matters - The investigation into Harmony Biosciences for potential securities law violations, coupled with concerns over its drug Wakix, raises red flags about the company's financial stability and future performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
